Investigational Agent
Trastuzumab or trastuzumab/pertuzumab
Key Eligibility Criteria Details
- FIGO 2009 stage IA-IVB non-recurrent, chemo-naive, HER2-positive endometrial serous carcinoma or carcinosarcoma
- Measurable or no-measurable disease allowed
- ECOG PS 0-2
- No prior chemo, biologic therapy, or targeted thearpy for treatment of endometrial cancer
- No prior radiation therapy for endometrial cancer
- No planned radiation
- No significant cardiac, lung, or intercurrent illness
- Patients with prior treatment with hormonal therapy are allowed